Tibet Aim Pharm.Inc. (002826.SZ) has released its semi-annual report for 2026, revealing robust financial performance with net profit attributable to shareholders reaching 66.6797 million yuan, marking a substantial 77.54% year-on-year increase.
During the reporting period, the company achieved operating revenue of 360 million yuan, up 15.47% from the previous year. The net profit excluding non-recurring gains and losses attributable to shareholders stood at 41.6428 million yuan, representing a 66.42% year-on-year growth. Basic earnings per share reached 0.36 yuan.
In the first half of 2026, the company executed a dual-track operational strategy, balancing the protection of existing business with the development of new growth opportunities. For its established operations, the company leveraged its lean production system to strengthen overall supply chain management, solidify the cost competitiveness of current products, and maintain stable market share, thereby securing a solid foundation for operating cash flow.
On the growth front, the company focused on unmet clinical needs, particularly among special patient populations such as elderly individuals with diabetes and those with liver or kidney dysfunction. By conducting market analysis and allocating resources based on the clinical characteristics of these target groups, the company is cultivating differentiated business lines and creating new value growth points for the future.
Comments